Sartorius Stedim Biotech, a top partner of the biopharmaceutical industry announced that, the company has now closed the acquisition of the chromatography division of the company ‘Novasep’ and the acquisition has been followed the approval from the Federal Trade Commission of the United States.
The business that has been acquired has generated the sales of around 40 million euros in the year 2020 at a profit margin of double digit and the majority of around 100 employees have been working at the Pompey site in the eastern region of France and some regions in the countries like India, China and the United States.
The acquired portfolio has been consisting of the chromatography systems that are primarily suited for the smaller biomolecules like the peptides, insulin and oligonucleotides and also the innovative systems for the continuous manufacturing of the biologics and since the year 2018, both the companies have also been together developing the optimized systems for a chromatography technology based on the membrane.
The acquisition has also been expected for generating the additional growth of the non-organic sales revenue of around one percent point in the year 2022, and the company ‘Sartorius Stedim Biotech has also updated the company’s forecast of sales revenue for the year 2022.
According to the company, the consolidates sales revenue has now been expected to be increased by around 15 to 19 percent along with the non-organic growth from the acquisitions that are estimated to contribute around 2 percent points.